Genfit SA (GNFT) Stock: Here’s Why It’s Tumbling


Genfit SA (GNFT) is making a move down in the market in today’s trading session. The company, focused on the biotechnology industry, is presently trading at $20.58 after falling -13.78% so far in today’s session. When it comes to biotechnology companies, there are a number of aspects that have the potential to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines centered around GNFT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-09-19 02:00PM Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
May-02-19 03:43PM Genfit, Cymbay Hope to Crack Large Liver Disease Market
May-01-19 11:12AM featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI
Apr-30-19 10:24AM 5 Stocks to Buy on New Analyst Coverage
Apr-25-19 10:11AM Top Ranked Momentum Stocks to Buy for April 25th

Nonetheless, any time investors are making an investing decision, investors should look at far more than just news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happening with Genfit SA.

What We’ve Seen From GNFT

While a move down on a single session, like what we’re seeing from Genfit SA may make some investors fearful, that by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always important to look at trends further out than a single session. When it comes to GNFT, here are the returns on investment that we’ve seen:

  • Past Seven Days – In the last seven days, GNFT has produced a price change in the amount of -15.45%.
  • Past 30 Days – The monthly returns from Genfit SA has been -12.57%.
  • Past 3 Months – In the last 3 months, the stock has generated a return on investment of 0
  • Past 6 Months – In the previous six months, we’ve seen a change that amounts to 0 from the stock.
  • This Year So Far – Since the open of this year GNFT has produced a ROI of -7.17%.
  • Annually – Lastly, over the past year, we’ve seen movement that works out to 0 from GNFT. Throughout this period, the stock has traded at a high of -21.60% and a low price of -1.08%.

Rations That Investors Should Think About

Digging into various key ratios associated with a stock can provide prospective investors a look of how risky and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to think about when looking at GNFT.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. The higher this ratio, the more investors believe that the price of the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to Genfit SA, the stock’s short ratio is 1.79.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they mature with only current assets or quick assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, the quick and current ratios can seem damning. However, several better companies in the biotech industry do have positive quick and current ratios. As far as GNFT, the quick and current ratios work out to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. In this particular case, the book to share value ratio comes in at 0.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotechnology space, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.

What Analysts Think About Genfit SA

While it’s never a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to use their opinions to validate your own due diligence when it comes to making investment decisions in the biotech sector. Below are the most recent moves that we’ve seen from analysts when it comes to GNFT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-24-19 Initiated SVB Leerink Outperform $58
Apr-22-19 Initiated Barclays Overweight

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in GNFT, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutional investors own 0 of Genfit SA. However, it is worth noting that the ownership held by institutions has changed in the amount of 0 throughout the past quarter.
  • Insider Moves – with regard to insiders, members of the management team and others close to GNFT currently own 0 of Genfit SA. Insider ownership of the company has moved 0 throughout the past 3 months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 31.17M shares of Genfit SA outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GNFT has a float of 29.62M.

I also find it important to follow the short percent. Think about it, if a large percentage of the float is shorted, the overall feeling among investors is that the equity is headed for a steep decline. As far as it relates to GNFT, the percentage of the float that is currently being sold short is 1.05%. Most investors would say that a concerning short percent of the float is anything over 40%. However, I have found that any short percent of the float over 26% is generally a play that comes with hefty risk.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, GNFT has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 9.40%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here